Please see below two important recent publications on the use of bedaquiline and delamanid (full disclosure-- I am co-author on first piece)
The first describes how to choose between bedaquiline and delamanid for an individual patient, and notes, "tuberculosis programmes should make both bedaquiline and delamanid available. Although there are no efficacy data to guide the choice of one agent over the other, there are clinical scenarios that favour either bedaquiline or delamanid, and there are some patients who will need both."
Full article attached; the link is here: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2817%2930309-0...
The second summarizes data on the use of bedaquiline in adolescents and children in MSF programs, noting, "Our experience suggests that bedaquiline can be used safely in children >12 years of age with appropriate monitoring and could be considered in younger children in select circumstances when benefits are likely to outweigh risks."
I hope this can stimulate use of the drugs in your setting. Are you able to access both bedaquiline and delamanid? Do you have patients who may require off-label use, such as patients who need both drugs due to extensive resistance, or adolescents?
Erica Lessem, MPH
Director, TB/HIV Project
Treatment Action Group
90 Broad St, Suite 2503
New York, NY 10004 USA